MCAS may cause repeated multisystem symptoms affecting the skin, digestion, circulation, breathing, headaches, fatigue, and pain sensitivity. Careful evaluation helps clarify what may be driving symptoms.
Learn how Dr. Nino explains Mast Cell Activation Syndrome (MCAS), its connection to chronic pain and inflammation, and the treatment options available to help manage symptoms.
Our team organizes conditions and treatments into related zones of expertise to make it easier to explore the care paths most relevant to your symptoms and goals.
Use the zone tags above to browse dedicated pages for each focus area, including services, providers, and what to expect during treatment.
Hi, I’m Dr. Nino Mikaberidze, and I’m a rheumatologist at Manhattan Pain Medicine. I’d like to talk about Mast Cell Activation Syndrome, or MCAS, because it’s something that can be difficult to recognize, but has a very real impact on how people feel day to day.
MCAS is not diagnosed by a single lab test. It’s what we call a clinical syndrome, which means we look at the full picture — your symptoms, patterns over time, and any objective findings — to understand what’s going on. At its core, MCAS is about mast cells overreacting. Mast cells are part of your immune system. Think of them as alarm cells — when they activate, they release chemical signals like histamine, prostaglandins, and leukotrienes.
In MCAS, those cells can activate too easily or at the wrong time, and that can lead to symptoms across multiple systems in the body. Patients may experience things like flushing, itching, hives, or swelling, but also gastrointestinal symptoms like cramping, nausea, or diarrhea. Some people notice respiratory symptoms, like wheezing or throat tightness, or more general symptoms like fatigue, headaches, or flu-like feelings.
One important feature is that symptoms are often episodic, meaning they come in flares. These flares can sometimes be triggered by things like heat, stress, illness, alcohol, certain foods, or medications. Because of that, a big part of diagnosis is recognizing the pattern.
We also look for whether symptoms improve with treatments that target mast cell activity. That may include medications like antihistamines, such as Allegra or Zyrtec, H2 blockers like famotidine, leukotriene blockers like montelukast, or mast cell stabilizers such as cromolyn or omalizumab in more complex cases. The goal is to calm that overactive response and help the body feel more stable over time.
If you’ve been experiencing symptoms that seem widespread, unpredictable, or difficult to explain, MCAS may be something worth evaluating. We’re here to help guide you through that process and create a plan that makes sense for your symptoms and your body.
Mast Cell Activation Syndrome, or MCAS, is a mast cell activation disorder that may cause repeated episodes of symptoms involving more than one body system. Symptoms can include flushing, itching, hives, swelling, GI upset, dizziness, blood pressure changes, breathing difficulty, headaches, fatigue, and pain sensitivity.
Because these symptoms can overlap with allergies, mastocytosis, autoimmune conditions, dysautonomia, migraine, hypermobility, gastrointestinal disorders, and chronic pain, Mast Cell Activation Syndrome diagnosis requires careful evaluation and objective criteria rather than symptoms alone.
At Manhattan Pain Medicine, evaluation begins with the full symptom pattern, including pain, neurologic symptoms, autonomic changes, inflammatory features, hypermobility, prior testing, and prior treatment response. For patients seeking Mast Cell Activation Syndrome treatment NYC, MPM’s role is not to assume MCAS explains every symptom.
The goal is to help clarify whether mast cell activation, inflammatory disease, dysautonomia, neuropathic pain, migraine, hypermobility, or another process may be contributing.
When appropriate, care may involve medication management, pain-focused treatment planning, and coordination with outside specialists such as allergy, immunology, rheumatology, gastroenterology, or neurology.
MCAS can be challenging because many patients describe symptoms that move across different systems: skin reactions, abdominal symptoms, dizziness, headaches, fatigue, brain fog, joint pain, neuropathic symptoms, and sensitivity to triggers. These symptoms may feel connected, but they are not specific to MCAS.
Similar patterns may occur with allergic disorders, histamine intolerance, mastocytosis, autoimmune-related pain, Ehlers-Danlos Syndrome, hypermobility spectrum disorder, POTS-like symptoms, migraine, chronic constipation, peripheral neuropathy, and other complex chronic pain conditions.
A responsible MCAS evaluation looks for a reproducible clinical pattern, objective evidence of mast cell mediator release, and response to mast cell-directed treatment. It also requires careful review of other explanations. This is where MPM’s diagnosis-first approach matters: the goal is to clarify the drivers of symptoms, not force a single label onto a complex presentation.
MCAS may sit at the intersection of several MPM Zones of Expertise, including Autoimmune and Inflammatory Disorders, Autonomic Dysfunction, and Hypermobility. This matters because patients rarely present with one isolated symptom. They may have flushing or hives alongside dizziness, migraine, constipation, joint instability, neuropathic pain, fatigue, or widespread sensitivity.
MPM uses the Zones of Expertise framework to evaluate how symptoms relate across systems. For some patients, immune or inflammatory activity may be central. For others, dysautonomia, hypermobility, migraine, nerve irritation, or chronic pain sensitization may be more important. By organizing care through these overlapping zones, MPM can help patients and referring providers think more clearly about which symptoms require further evaluation, which diagnoses may be connected, and which treatment pathways may be appropriate.
I cannot say enough good things about Manhattan Pain Medicine. From the moment I walked in, I felt truly cared for and taken seriously. Dr. Nino Mikaberidze, Director of Rheumatology, is exceptional — knowledgeable, compassionate, and incredibly thorough. She takes the time to listen, explains every...
The best care I've received as a chronic pain patient. I traveled from out of state to visit Manhattan Pain Medicine because I could not find knowledgeable doctors in my hometown for my hypermobility, and Ehlers-Danlos syndrome symptoms and comorbidities. Let me tell you, it was worth every travel e...
I was injured in a bicycle accident over 8 years ago. I’ve suffered throughout the years since my accident with nothing seeming to work. PT, Yoga, lifestyle changes, NOTHNG! I finally made an appointment with Dr Kane and I’m feeling an improvement in my life. I no longer stay up all night in pain, a...
One of the best experiences, if not the best, I have ever had at the doctor’s office. From the front desk to the nurses to the PA assisting the doctor this was a great experience. Dr.Nino actually listened to me and came up with a game plan. Would recommend this practice to as many people as I could...
I have very unique & severe nerve pain from CRPS which has no known specific cure. Dr. Siefferman has a huge tool box, far greater than the other 23 Drs. I have seen. He saved me from jumping off a bridge and continues to help me with both treatments and advice. Dr. S. is in a different league!
After two years of searching and feeling lost and let down, I finally found real help at Manhattan Pain Medicine. With Dr. Siefferman, Adam Rosenberg, Dr. Mikaberidze, and the whole team, I feel heard, supported and understood. Every symptom is being considered and I’m finally getting answers with m...
Why is Dr Dr. Tayyaba Ahmed one of the top pevic Floor specialists - 1- She wants to know a full history of what led the patient to get to this point. 2 - She listens intensley to the patient 3- She does not rush you 4- Extremely skilled at giving pelvic floor injections 5- I thank my luck stars she...
The staff was friendly and helpful. Dr. Siefferman was thoughtful, listened, asked questions and proposed simple safe ways to come to further conclusions regarding my pain and discomfort. The office staff including Dr. Siefferman is responsive even after the initial in-person visit. Very pleased.
Dr. Siefferman is a brilliant provider. While my pain is still a work in progress, Dr Siefferman always gives me options and explains his reasoning behind things. He listens to my feedback and concerns. I never feel rushed; and am grateful he works to meet me where I am. I highly recommend him.
What a great find! They listen to me, I listen to them and the diagnosis is made and a plan developed to develop an approach to treat all of my chronic pain. I wish I could have discovered this type of treatment sooner. This doctor and group give me hope.
Mast Cell Activation Syndrome, or MCAS, is a mast cell activation disorder that may cause repeated episodes of symptoms similar to allergic or anaphylaxis-type reactions. Mast cells are immune cells that release mediators such as histamine and other inflammatory chemicals. In MCAS, these mediators may affect multiple systems, including the skin, gastrointestinal tract, cardiovascular system, respiratory system, and nervous system. Patients may report flushing, itching, hives, swelling, abdominal symptoms, dizziness, headaches, fatigue, or pain sensitivity. Because these symptoms are not specific to MCAS, diagnosis requires more than symptom reporting.
MCAS diagnosis usually requires a combination of clinical pattern recognition and objective findings. Common diagnostic frameworks include recurrent symptoms consistent with mast cell mediator release, a measurable rise in mast cell mediators during episodes, and improvement with medications that block or reduce mast cell mediator effects. Testing may include serum tryptase collected during a flare and at baseline, and in some cases urine mediator testing. Timing matters because certain markers are most useful when collected close to an acute episode. Symptoms alone are not enough to confirm MCAS, and other conditions often need to be considered.
MCAS is generally described as a mast cell activation disorder, not a typical autoimmune disease. Autoimmune diseases involve the immune system mistakenly attacking the body’s own tissues. MCAS involves inappropriate release of mast cell mediators, which can cause symptoms across multiple systems. That said, MCAS-like symptoms may overlap with autoimmune-related pain, inflammatory disorders, dysautonomia, hypermobility, migraine, and gastrointestinal conditions. Some patients may also carry more than one diagnosis. MPM evaluates these overlaps carefully so symptoms are not automatically attributed to one condition without appropriate clinical support.
MCAS symptoms can vary, but they often involve more than one body system. Patients may report flushing, itching, hives, swelling, abdominal pain, nausea, diarrhea, constipation, dizziness, changes in heart rate or blood pressure, shortness of breath, fatigue, headaches, migraine-like symptoms, neuropathic pain, or widespread sensitivity. These symptoms may occur in episodes or flares and may be triggered by foods, medications, temperature changes, stress, infections, fragrances, or other exposures. Because many conditions can cause similar symptoms, the pattern, timing, objective testing, and response to treatment all matter during evaluation.
MCAS treatment is typically individualized and may include trigger avoidance, H1 and H2 antihistamines, leukotriene modifiers, mast cell stabilizers, and in select cases medications such as omalizumab or short courses of corticosteroids for severe flares. Patients at risk for anaphylaxis may be prescribed epinephrine by an appropriate clinician. At MPM, treatment planning also considers related pain patterns, inflammatory conditions, dysautonomia, hypermobility, migraine, neuropathy, and chronic symptom burden. MPM-related care may include medication management, biologics for appropriate inflammatory or autoimmune conditions, pain psychology, or selected infusion therapies for specific pain indications, not as cures for MCAS.
Some patients with suspected MCAS also report hypermobility, Ehlers-Danlos Syndrome, POTS-like symptoms, migraine, constipation, neuropathy, or chronic pain. These conditions can overlap in real clinical presentations, but overlap does not prove that one condition caused the others. This distinction is important. MPM evaluates the full clinical picture to determine whether mast cell activation, autonomic dysfunction, hypermobility, inflammatory disease, neuropathic pain, migraine, or another process appears to be driving the patient’s symptoms. This helps avoid oversimplifying a complex condition and supports more targeted care planning.
MCAS can be associated with severe allergic reactions, including anaphylaxis. Symptoms such as swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, fainting, loss of consciousness, severe dizziness, or signs of low blood pressure should be treated as urgent. Patients who have been prescribed epinephrine should use it as directed and seek emergency care immediately. Emergency evaluation is important because anaphylaxis can progress quickly and may involve breathing or cardiovascular compromise. This page is not a substitute for emergency care or individualized medical advice.
Yes. MPM evaluates complex symptom patterns that may involve chronic pain, autonomic dysfunction, hypermobility, inflammatory symptoms, migraine, neuropathy, and gastrointestinal overlap. For patients seeking an MCAS specialist Manhattan or MCAS doctor NYC, MPM’s role is to help clarify the pain and multisystem components of the presentation and coordinate care when additional specialists are needed. Evaluation may include review of prior diagnoses, symptom patterns, medications, testing, and related conditions. The goal is to understand what is most likely contributing to symptoms and build a responsible, stepwise plan.
Before care begins, our team helps patients understand the practical side of treatment, including insurance verification, out-of-network benefits, cost-share estimates, self-pay options, and billing questions. We believe patients should have as much clarity as possible before moving forward.
Mast Cell Activation Syndrome, often called MCAS, is a mast cell activation disorder that may cause repeated episodes of symptoms across more than one body system. Mast cells are immune cells involved in allergic and inflammatory responses. When activated, they release mediators such as histamine, tryptase, prostaglandins, leukotrienes, and other chemicals that can affect the skin, blood vessels, digestive tract, airways, and nervous system.
In MCAS, the concern is not simply that symptoms are uncomfortable or widespread. The concern is whether mast cells are releasing mediators in a way that is inappropriate, recurrent, and clinically meaningful. This distinction matters because many people experience flushing, itching, dizziness, GI symptoms, headaches, fatigue, or pain for reasons that are not MCAS. A diagnosis-first evaluation helps determine whether mast cell activation is truly part of the picture or whether another condition is a better explanation.
MCAS symptoms can vary from patient to patient. Some people describe skin symptoms such as flushing, itching, hives, or swelling. Others have gastrointestinal symptoms such as abdominal discomfort, nausea, diarrhea, constipation, reflux, or food sensitivity. Some experience dizziness, changes in heart rate, blood pressure symptoms, fatigue, brain fog, shortness of breath, headaches, migraine-like episodes, neuropathic pain, or widespread pain sensitivity.
The symptoms may occur in flares and may involve multiple systems at once. For example, a patient may develop flushing, abdominal cramping, lightheadedness, and headache during the same episode. Another patient may notice symptoms after certain foods, medications, heat, stress, infections, or environmental exposures. These patterns can be useful, but they are not enough to confirm MCAS.
MCAS diagnosis requires more than a checklist of symptoms. Current diagnostic frameworks generally look for three elements: recurrent symptoms consistent with mast cell mediator release, objective evidence of elevated mast cell mediators during an episode compared with baseline, and clinical improvement with mast cell-directed treatment. Mediator testing may include serum tryptase and, in some cases, urine markers collected within a specific time window after a flare.
This is one reason MCAS can be difficult to diagnose. Testing may be normal if it is collected at the wrong time, if the wrong marker is used, or if the symptoms are being driven by another condition. At the same time, symptoms that feel like MCAS can overlap with allergic disorders, histamine intolerance, mastocytosis, autoimmune disease, dysautonomia, migraine, gastrointestinal disorders, hypermobility spectrum disorder, Ehlers-Danlos Syndrome, peripheral neuropathy, and complex chronic pain.
Many patients searching for Mast Cell Activation Syndrome treatment in Manhattan are not dealing with MCAS symptoms alone. They may also have hypermobility, EDS, POTS-like symptoms, chronic migraine, chronic constipation, neuropathy, joint instability, inflammatory pain, or widespread pain sensitivity. These overlaps are clinically important, but they must be discussed carefully. Having symptoms in several categories does not automatically prove that MCAS is the cause.
MPM evaluates these patterns through its Zones of Expertise, including Autoimmune and Inflammatory Disorders, Autonomic Dysfunction, and Hypermobility. This structure helps the care team consider whether symptoms may be immune-mediated, inflammatory, autonomic, neurologic, musculoskeletal, hypermobility-related, or multifactorial. It also helps avoid a fragmented approach where each symptom is treated separately without understanding how the full clinical picture fits together.
MCAS treatment is usually individualized and may include H1 and H2 blockers, leukotriene modifiers, mast cell stabilizers, trigger management, and in selected cases biologic therapy such as omalizumab under the care of an appropriate clinician. Epinephrine may be necessary for patients at risk of anaphylaxis. Corticosteroids are generally reserved for more severe flares or specific clinical circumstances, rather than used as a routine long-term strategy.
For patients with chronic pain, treatment planning may also need to address neuropathic pain, migraine, joint instability, inflammatory pain, central sensitization, or the burden of long-term symptoms. MPM-related treatment options may include medication management, biologics for relevant autoimmune or inflammatory conditions, pain psychology for chronic symptom management, and selected lidocaine or ketamine infusions for appropriate neuropathic or centralized pain patterns. These treatments should not be described as MCAS cures. Instead, they may be part of a broader plan when pain and mast cell-related symptoms overlap.
Some MCAS-related or MCAS-like reactions can become emergencies. Swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, fainting, loss of consciousness, severe dizziness, or low blood pressure may indicate anaphylaxis or another serious reaction. Patients who have been prescribed epinephrine should use it as directed and seek emergency care immediately.
MPM approaches suspected MCAS by first listening carefully to the patient’s full history. This includes symptom timing, flare patterns, triggers, prior diagnoses, medications, allergies, lab work, imaging, specialist notes, and response to previous treatments. The goal is to understand whether mast cell activation appears likely, whether another condition may be driving symptoms, and whether multiple systems need to be evaluated together.
For some patients, the next step may involve coordination with allergy, immunology, rheumatology, gastroenterology, neurology, cardiology, or other specialists. For others, the focus may be pain management, autonomic symptom evaluation, hypermobility-related care, migraine care, or treatment of inflammatory pain. MPM’s diagnosis-first model is designed to support patients with complex chronic pain NYC and multisystem symptoms by clarifying the most relevant drivers and building a stepwise, coordinated plan.
